Esophageal Disease Clinical Trial
Official title:
Treatment Response of High-dose and Standard-dose Rabeprazole for Gastroesophageal Reflux Disease With Extra-esophageal Manifestations: a Single-center, Randomized, Open-label Trial.
This is a single-center, randomized, open-label clinical study to assess the treatment response of high-dose rabeprazole compared with standard-dose rabeprazole in patients with extra-esophageal manifestations of gastroesophageal reflux disease.
Gastroesophageal reflux disease is a condition in which reflux of stomach contents into the
esophagus. This disease can be classified in to two subtypes according to the symptoms;
Typical symptoms such as heartburn and regurgitation, and atypical symptoms (extra-esophageal
symptoms) such as chronic cough, asthma, non-cardiac chest pain, globus sensation, etc.
Acid suppression with proton pump inhibitors is the mainstream of therapy for the
extra-esophageal manifestation as well as the typical symptoms of gastroesophageal reflux
disease.
However, there is controversy about the efficacy of proton pump inhibitors on
extra-esophageal reflux.
Therefore, we aimed to assess the effect of proton pump inhibotor (rabeprazole) on the
extra-esophageal manifestation of gastroesophageal reflux disease, through comparison of
treatment response with high-dose and standard-dose rabeprazole.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02105506 -
Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses
|
N/A | |
| Completed |
NCT01360515 -
A Study of Disposable Transnasal Esophagoscope
|
N/A | |
| Recruiting |
NCT02526095 -
The French EsoGastricTumours Data Base
|
||
| Completed |
NCT03998969 -
Efficacy of DA-5204 on Gastroesophageal Reflux Disease
|
Phase 3 | |
| Completed |
NCT01927016 -
Outcomes After Esophageal Cancer Surgery
|
N/A |